Wall Street is Behind the Curve on Foreign Exchange Impact
Insights - Across the market, multinational companies are blaming missed earnings and lower-than-expected 2015 guidance on foreign exchange effects and cheap oil.
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Regeneron’s New Cholesterol Drug is a Month Ahead of Amgen’s: Is that Worth $70 Million?
Insights - That's what Regeneron (REGN) and Sanofi (SNY) paid for a FDA Priority Review Voucher that will shorten the review time for the PCSK9 inhibitor, alirocumab.
Read now
The Highest Biotech Fliers Last Week were the Hardest Hit this Week
“New” Tekmira Emerges as HBV Frontrunner
Research - This is the first clinical step for “new Tekmira”. Announced last week, Tekmira is merging with OnCore Biopharma to focus on therapeutics for Hepatitis B.
Read now
Medivation Reports Success in Latest Cancer Trial
Insights - The trial was successful, with enzalutamide improving progression-free survival (PFS) meaningfully compared to bicalutamide.
Read now
What Does it Mean When EVERYONE’s Optimistic About Biotech Stocks?
Tekmira Just Became a Must-Own Stock for 2015
Research - Tekmira Pharmaceuticals (TKMR) is merging with privately held OnCore Biopharma, which develops drugs targeting the Hepatitis B virus (HBV).
Premium